Structure-Activity-Relationship Exploration and Animal Validation of Novel Assembly Modulator Small Molecule Chemical Series with Pan-Cancer Selective Cytotoxicity
Lingappa, A. F.; Mallesh, S.; Michon, M.; Shivarudraswamy, D.; Lin, J.; Prasad, M. D.; Dey, D.; Solas, D.; Lingappa, V. R.
Show abstract
We recently described a novel class of chemical compounds initially identified as modulators of host-catalyzed HIV capsid assembly, that have been advanced to display broad anti-tumor cytotoxicity. Here we explore in more detail the structure-activity-relationship (SAR) of the chemical series. PAV-0805, an advanced analog, was found to be nontoxic at 10mg/kg in mice and nontoxic to healthy human peripheral blood mononuclear cells (PBMCs). PAV-0805 has broad anti-cancer activity in the NCI-60 cancer cell line screen, exhibiting cytotoxicity to a diversity of brain, breast, colon, lung, ovarian prostate, renal, and skin and blood cancers. In the aggressive 4T1 mouse allograft breast cancer model, PAV-0805 reduced tumor growth and metastasis when treatment was initiated early (primary tumor volume of 50mm3) or late (primary tumor volume of 500mm3). In both cases, treatment with PAV-0805 inhibited both tumor growth and metastasis to a degree comparable to early treatment with paclitaxel. PAV-0805 targets Protein Disulfide Isomerase in a dynamic multi-protein complex comprised of gene products involved in the cancer hallmarks of resisting cell death and reprogramming energy metabolism.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys 95%
- Development of potent and selective CK1α Molecular Glue Degraders 95%
- Design, synthesis and cellular characterization of a new class of IPMK kinase inhibitors 94%
Similar papers in this journal
- Inhibition of a Selective SWI/SNF Function Synergizes with ATR Inhibitors in Cancer Cell Killing 95%
- Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor 94%
- Small Molecule Activation of NAPE-PLD Enhances Efferocytosis by Macrophages 94%
Similar papers in this journal
- Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A 96%
- PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor 95%
- A screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3) 95%
Similar papers in this journal
- A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment. 95%
- A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease. 95%
- CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines. 94%
Similar papers in this journal
- CHI3L1-Targeted Small Molecules as Glioblastoma Therapies: Virtual Screening-Based Discovery, Biophysical Validation, Pharmacokinetic Profiling, and Evaluation in Glioblastoma Spheroids 95%
- Development of pyrazolopyrimidine based macrocyclic kinase inhibitors targeting AAK1 95%
- Modulation of endogenous opioid signaling by inhibitors of puromycin sensitive aminopeptidase 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.